The market has been high on Ironwood Pharmaceuticals, Inc. (IRWD) stock recently. IRWD gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.
Ironwood Pharmaceuticals, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IRWD!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With IRWD Stock Today?
Ironwood Pharmaceuticals, Inc. (IRWD) stock is trading at $10.36 as of 3:27 PM on Tuesday, Dec 5, a decline of -$0.18, or -1.66% from the previous closing price of $10.53. The stock has traded between $10.28 and $10.65 so far today. Volume today is 1,616,690 compared to average volume of 2,039,528.
To screen for more stocks like Ironwood Pharmaceuticals, Inc. click here.
More About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Click Here to get the full Stock Report for Ironwood Pharmaceuticals, Inc. stock.